Q-Line's Unit 4 unlocks 3-4x capacity; reagents power margin renaissance
FY26 revenue ₹341.7 cr, EBITDA up 39% as manufactured reagents hit 70% of mix. CEO says no additional capex needed for growth.
What's new
- Unit 4 Lucknow commissioned, enabling 3-4x current reagent business without incremental capex.
- Reagent revenue grew 35% in FY26, now 70% of total revenue (vs 100% traded prior).
- Gross margin expanded 750 bps to 60.8% driven by manufacturing shift.
- Selectra Pro M installations crossed 1,550, with 450 added in FY26.
Themes from the call
Demand
Reagent revenue up 35%, install base expanding with 1,550+ Selectra Pro M units in 2.3 years; 50-55% growth in hematology analyzers.
Margins
Gross margin rose 750 bps to 60.8% as manufactured reagents (60-65% margin) replaced lower-margin traded goods (50% margin).
Capital allocation
Unit 4 capex complete; CEO states no further capex needed for 3-4x revenue growth, releasing fixed-cost absorption.
Guidance watch
- FY27 revenue growth target 30-35% (30-35% reagent growth, 300-400 analyzer installations, exports ₹6 cr up from ₹1.2 cr, CDMO ₹10 cr).
- Unit 4 capacity utilization target 25-30% by end FY27, a falsifiable near-term marker.
Risk flags
- Of 1,500+ installed analyzers, only 400-500 generate active reagent orders; activation of dormant units is key.
- International expansion (exports ₹6 cr target) and CDMO (₹10 cr target) are from a low base and carry execution risk.
Key quotes
-
"With this facility, we can do at least 3 to 4 times the business we are doing now without additional capital."
— Ajay Kumar Mahanty, CEO -
"Manufactured reagents now 70% of mix, driving 60-65% gross margins against 50% on traded."
— Management, Q4 FY26 call
The brief
Q-Line Biotech delivered a defining year in FY26, with Unit 4 Lucknow coming online and a razor-and-blade model shifting into higher gear. Revenue grew 9% to ₹341.7 crore, but the real story is the mix: manufactured reagents now account for 70% of revenue, up from virtually zero three years ago. That shift added 750 basis points to gross margins, lifting them to 60.8%, and pushed EBITDA up 39% to ₹98.1 crore. The company is now a capital-light compounding machine. CEO Ajay Kumar Mahanty says Unit 4 alone can handle 3-4 times current reagent volumes without fresh capex.
Guidance for FY27 is ambitious but credible: 30-35% revenue growth, driven by 30-35% reagent growth, 300-400 new analyzer placements, and small contributions from exports (₹6 crore) and CDMO (₹10 crore). The Selectra Pro M has crossed 1,550 installations in 2.3 years, each generating roughly ₹3 lakh annual reagent consumption. But the real kicker is that only 400-500 of the total install base are actively ordering; activating dormant units in public health centers alone could add material near-term revenue.
Risks are real but manageable. International and CDMO businesses are nascent; exports were just ₹1.2 crore in FY26. The CDMO hinges on European partner negotiations. Still, the core domestic reagent engine is firing on all cylinders, and Unit 4 removes the capacity bottleneck that blocked government tenders. If management can hit 25-30% utilisation by year-end, a stated target, profitability will improve further as fixed costs are spread across higher volumes.
Q-Line's story is no longer about potential. It's about a proven model that now has the capacity to scale without burning cash.
Q-Line's reagent-led model is capital-light and margin-rich — the next milestone is activating dormant installations and proving exports.